Citations (60)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Lifei Ma, Guiqin Song, Meiyu Li, Xiuqing Hao, Yong Huang, Jinping Lan, Siqian Yang, Zetian Zhang, Guohui Zhang & Jiao Mu. (2020) Construction and Comprehensive Analysis of a ceRNA Network to Reveal Potential Novel Biomarkers for Triple-Negative Breast Cancer. Cancer Management and Research 12, pages 7061-7075.
Read now
Read now
Ya Wang, Hanning Li, Jingjing Ma, Tian Fang, Xiaoting Li, Jiahao Liu, Henok Kessete Afewerky, Xiong Li & Qinglei Gao. (2019) Integrated Bioinformatics Data Analysis Reveals Prognostic Significance Of SIDT1 In Triple-Negative Breast Cancer. OncoTargets and Therapy 12, pages 8401-8410.
Read now
Read now
Articles from other publishers (58)
Xi Cao, Yu Song, Huanwen Wu, Xinyu Ren, Qiang Sun & Zhiyong Liang. (2023) C-X-C Motif Chemokine Ligand 9 Correlates with Favorable Prognosis in Triple-Negative Breast Cancer by Promoting Immune Cell Infiltration. Molecular Cancer Therapeutics 22:12, pages 1493-1502.
Crossref
Crossref
Lie Chen, Cui-Cui Liu, Si-Yuan Zhu, Jing-Yu Ge, Yu-Fei Chen, Ding Ma, Zhi-Ming Shao & Ke-Da Yu. (2023) Multiomics of HER2-low triple-negative breast cancer identifies a receptor tyrosine kinase–relevant subgroup with therapeutic prospects. JCI Insight 8:22.
Crossref
Crossref
Shania Pintor, Alma Lopez, David Flores, Brianda Lozoya, Bipul Soti, Rishi Pokhrel, Joaquin Negrete, Michael W. Persans, Robert Gilkerson, Bonnie Gunn & Megan Keniry. (2023) FOXO1 promotes the expression of canonical WNT target genes in examined basal‐like breast and glioblastoma multiforme cancer cells. FEBS Open Bio 13:11, pages 2108-2123.
Crossref
Crossref
Amitha Muraleedharan, Sagar Kumar & Rashmi Mittal. 2023. Therapeutic Drug Targets and Phytomedicine For Triple Negative Breast Cancer. Therapeutic Drug Targets and Phytomedicine For Triple Negative Breast Cancer
73
98
.
Guoyu Wu & Yuchao Li. (2022) TGF-β induced reprogramming and drug resistance in triple-negative breast cells. BMC Pharmacology and Toxicology 23:1.
Crossref
Crossref
Jing Chen, Da Ma, Cuicui Zeng, Lorenzo V. White, Huanqing Zhang, Yinglai Teng & Ping Lan. (2022) Solasodine suppress MCF7 breast cancer stem-like cells via targeting Hedgehog/Gli1. Phytomedicine 107, pages 154448.
Crossref
Crossref
Kangjian Wang, Zongkai Zou, Haolin Shen, Guimei Huang & Shuping Yang. (2022) Calcification, Posterior Acoustic, and Blood Flow: Ultrasonic Characteristics of Triple-Negative Breast Cancer. Journal of Healthcare Engineering 2022, pages 1-9.
Crossref
Crossref
Yi-Yu Chen, Jing-Yu Ge, Si-Yuan Zhu, Zhi-Ming Shao & Ke-Da Yu. (2022) Copy number amplification of ENSA promotes the progression of triple-negative breast cancer via cholesterol biosynthesis. Nature Communications 13:1.
Crossref
Crossref
Sharita Meharry, Robert Borotkanics, Reena Ramsaroop & Fabrice Merien. (2021) Risk factors at five-year survival in grade 3 breast cancer: a retrospective observational study of the New Zealand population. BMC Public Health 21:1.
Crossref
Crossref
Yongpeng Li, Yanan Tan, Lijuan Wen, Zhihao Xing, Changxu Wang, Liuhui Zhang, Kai Wu, Haiyan Sun, Yuqing Li, Qifang Lei & Song Wu. (2021) Overexpression of BIRC6 driven by EGF-JNK-HECTD1 signaling is a potential therapeutic target for triple-negative breast cancer. Molecular Therapy - Nucleic Acids 26, pages 798-812.
Crossref
Crossref
Tian Tian, Yangzhi Zhao, Jingying Zheng, Shunzi Jin, Zhongshan Liu & Tiejun Wang. (2021) Circular RNA: A potential diagnostic, prognostic, and therapeutic biomarker for human triple-negative breast cancer. Molecular Therapy - Nucleic Acids 26, pages 63-80.
Crossref
Crossref
Xin Xu, Xiangyan Ruan, Ying Zhang, Guiju Cai, Rui Ju, Yu Yang, Jiaojiao Cheng & Muqing Gu. (2021) Comprehensive Analysis of the Implication of PGRMC1 in Triple-Negative Breast Cancer. Frontiers in Bioengineering and Biotechnology 9.
Crossref
Crossref
Yu-Zhu Zhang, Jia-Yao Yang, Rui-Xian Wu, Chen Fang, Hai Lu, Hua-Chao Li, Dong-Mei Li, Hua-Li Zuo, Li-Ping Ren, Xiao-Yuan Liu, Rui Xu, Jia-Huai Wen, Hsien-Da Huang, Ri Hong & Qian-Jun Chen. (2021) Network Pharmacology–Based Identification of Key Mechanisms of Xihuang Pill in the Treatment of Triple-Negative Breast Cancer Stem Cells. Frontiers in Pharmacology 12.
Crossref
Crossref
Navid Mohammad Mirzaei, Sumeyye Su, Dilruba Sofia, Maura Hegarty, Mohamed H. Abdel-Rahman, Alireza Asadpoure, Colleen M. Cebulla, Young Hwan Chang, Wenrui Hao, Pamela R. Jackson, Adrian V. Lee, Daniel G. Stover, Zuzana Tatarova, Ioannis K. Zervantonakis & Leili Shahriyari. (2021) A Mathematical Model of Breast Tumor Progression Based on Immune Infiltration. Journal of Personalized Medicine 11:10, pages 1031.
Crossref
Crossref
Xinkui Liu, Yang Wu, Yingying Zhang, Dechao Bu, Chao Wu, Shan Lu, Zhihong Huang, Yurong Song, Yi Zhao, Fengying Guo, Peizhi Ye, Changgeng Fu, Liangliang Shen, Jingyuan Zhang, Haojia Wang, Xianchun Duan & Jiarui Wu. (2021) High Throughput Transcriptome Data Analysis and Computational Verification Reveal Immunotherapy Biomarkers of Compound Kushen Injection for Treating Triple-Negative Breast Cancer. Frontiers in Oncology 11.
Crossref
Crossref
Wenting Peng, Caijin Lin, Shanshan Jing, Guanhua Su, Xi Jin, Genhong Di & Zhiming Shao. (2021) A Novel Seven Gene Signature-Based Prognostic Model to Predict Distant Metastasis of Lymph Node-Negative Triple-Negative Breast Cancer. Frontiers in Oncology 11.
Crossref
Crossref
Hye-Youn Kim, Young-Mi Kim & Suntaek Hong. (2021) DNAJB9 suppresses the metastasis of triple-negative breast cancer by promoting FBXO45-mediated degradation of ZEB1. Cell Death & Disease 12:5.
Crossref
Crossref
Maria Francesca Santolla, Marianna Talia & Marcello Maggiolini. (2021) S100A4 Is Involved in Stimulatory Effects Elicited by the FGF2/FGFR1 Signaling Pathway in Triple-Negative Breast Cancer (TNBC) Cells. International Journal of Molecular Sciences 22:9, pages 4720.
Crossref
Crossref
Ramesh Elango, Radhakrishnan Vishnubalaji, Hibah Shaath & Nehad M. Alajez. (2021) Molecular subtyping and functional validation of TTK, TPX2, UBE2C, and LRP8 in sensitivity of TNBC to paclitaxel. Molecular Therapy - Methods & Clinical Development 20, pages 601-614.
Crossref
Crossref
Song-Yang Wu, Hai Wang, Zhi-Ming Shao & Yi-Zhou Jiang. (2020) Triple-negative breast cancer: new treatment strategies in the era of precision medicine. Science China Life Sciences 64:3, pages 372-388.
Crossref
Crossref
Rosamaria Lappano, Marianna Talia, Francesca Cirillo, Damiano Cosimo Rigiracciolo, Domenica Scordamaglia, Rita Guzzi, Anna Maria Miglietta, Ernestina Marianna De Francesco, Antonino Belfiore, Andrew H. Sims & Marcello Maggiolini. (2020) The IL1β-IL1R signaling is involved in the stimulatory effects triggered by hypoxia in breast cancer cells and cancer-associated fibroblasts (CAFs). Journal of Experimental & Clinical Cancer Research 39:1.
Crossref
Crossref
Bruna Cristina Borges, Isadora Akemi Uehara, Marlus Alves dos Santos, Flávia Alves Martins, Fernanda Carvalho de Souza, Álvaro Ferreira Junior, Felipe Andrés Cordero da Luz, Mylla Spirandelli da Costa, Ana Flávia Oliveira Notário, Daiana Silva Lopes, Samuel Cota Teixeira, Thaise Lara Teixeira, Patrícia de Castilhos, Claudio Vieira da Silva & Marcelo José Barbosa Silva. (2020) The Recombinant Protein Based on Trypanosoma cruzi P21 Interacts With CXCR4 Receptor and Abrogates the Invasive Phenotype of Human Breast Cancer Cells. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Yanding Zhao, Evelien Schaafsma & Chao Cheng. (2020) Gene signature‐based prediction of triple‐negative breast cancer patient response to Neoadjuvant chemotherapy. Cancer Medicine 9:17, pages 6281-6295.
Crossref
Crossref
Jen-Hwey Chiu, Ling-Ming Tseng, Tzu-Ting Huang, Chun-Yu Liu, Jir-You Wang, Ching-Po Huang, Yi-Fang Tsai & Chih-Yi Hsu. (2020) MEGF11 is related to tumour recurrence in triple negative breast cancer via chemokine upregulation. Scientific Reports 10:1.
Crossref
Crossref
Sanaa Ben Djemaa, Katel Hervé-Aubert, Laurie Lajoie, Annarita Falanga, Stefania Galdiero, Steven Nedellec, Martin Soucé, Emilie Munnier, Igor Chourpa, Stéphanie David & Emilie Allard-Vannier. (2019) gH625 Cell-Penetrating Peptide Promotes the Endosomal Escape of Nanovectorized siRNA in a Triple-Negative Breast Cancer Cell Line. Biomacromolecules 20:8, pages 3076-3086.
Crossref
Crossref
Yi-Zhou Jiang, Ding Ma, Chen Suo, Jinxiu Shi, Mengzhu Xue, Xin Hu, Yi Xiao, Ke-Da Yu, Yi-Rong Liu, Ying Yu, Yuanting Zheng, Xiangnan Li, Chenhui Zhang, Pengchen Hu, Jing Zhang, Qi Hua, Jiyang Zhang, Wanwan Hou, Luyao Ren, Ding Bao, Bingying Li, Jingcheng Yang, Ling Yao, Wen-Jia Zuo, Shen Zhao, Yue Gong, Yi-Xing Ren, Ya-Xin Zhao, Yun-Song Yang, Zhenmin Niu, Zhi-Gang Cao, Daniel G. Stover, Claire Verschraegen, Virginia Kaklamani, Anneleen Daemen, John R. Benson, Kazuaki Takabe, Fan Bai, Da-Qiang Li, Peng Wang, Leming Shi, Wei Huang & Zhi-Ming Shao. (2019) Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell 35:3, pages 428-440.e5.
Crossref
Crossref
Xi Shen, Jianxin Zhong, Pan Yu, Qiuyang Zhao & Tao Huang. (2019) YY1-regulated LINC00152 promotes triple negative breast cancer progression by affecting on stability of PTEN protein. Biochemical and Biophysical Research Communications 509:2, pages 448-454.
Crossref
Crossref
Hong Li, Yuefeng Zhang, Hsiao-Huei Chen, En Huang, Hailin Zhuang, Dan Li & Feng Ni. (2019) Rosmarinic acid inhibits stem-like breast cancer through hedgehog and Bcl-2/Bax signaling pathways. Pharmacognosy Magazine 15:65, pages 600.
Crossref
Crossref
Erik De Clercq. (2019) Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration. Antiviral Chemistry and Chemotherapy 27, pages 204020661982938.
Crossref
Crossref
Meiying Li, Fei Ma, Jiayu Wang, Qing Li, Pin Zhang, Peng Yuan, Yang Luo, Ruigang Cai, Ying Fan, Shanshan Chen, Qiao Li & Binghe Xu. (2018) Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy. Chinese Journal of Cancer 37:1.
Crossref
Crossref
Sanaa Ben Djemaa, Stephanie David, Katel Hervé-Aubert, Annarita Falanga, Stefania Galdiero, Emilie Allard-Vannier, Igor Chourpa & Emilie Munnier. (2018) Formulation and in vitro evaluation of a siRNA delivery nanosystem decorated with gH625 peptide for triple negative breast cancer theranosis. European Journal of Pharmaceutics and Biopharmaceutics 131, pages 99-108.
Crossref
Crossref
Sergio Liarte, José Luis Alonso-Romero & Francisco José Nicolás. (2018) SIRT1 and Estrogen Signaling Cooperation for Breast Cancer Onset and Progression. Frontiers in Endocrinology 9.
Crossref
Crossref
K.X. Zhou, L.H. Xie, X. Peng, Q.M. Guo, Q.Y. Wu, W.H. Wang, G.L. Zhang, J.F. Wu, G.J. Zhang & C.W. Du. (2018) CXCR4 antagonist AMD3100 enhances the response of MDA-MB-231 triple-negative breast cancer cells to ionizing radiation. Cancer Letters 418, pages 196-203.
Crossref
Crossref
Quan Li, Wenxu Jin, Yefeng Cai, Fang Yang, Endong Chen, Danrong Ye, Qingxuan Wang & Xiaoxiang Guan. (2017) Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer. Biochemical and Biophysical Research Communications 485:3, pages 693-697.
Crossref
Crossref
Asaad Azarnezhad & Parvin Mehdipour. 2017. Cancer Genetics and Psychotherapy. Cancer Genetics and Psychotherapy
79
389
.
Yi-Rong Liu, Yi-Zhou Jiang, Xiao-En Xu, Ke-Da Yu, Xi Jin, Xin Hu, Wen-Jia Zuo, Shuang Hao, Jiong Wu, Guang-Yu Liu, Gen-Hong Di, Da-Qiang Li, Xiang-Huo He, Wei-Guo Hu & Zhi-Ming Shao. (2016) Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. Breast Cancer Research 18:1.
Crossref
Crossref
J.L. Dillon, S.M. Mockus, G. Ananda, V. Spotlow, W.A. Wells, G.J. Tsongalis & J.D. Marotti. (2016) Somatic gene mutation analysis of triple negative breast cancers. The Breast 29, pages 202-207.
Crossref
Crossref
Klaas de Lint, Jos B. Poell, Hayssam Soueidan, Katarzyna Jastrzebski, Jordi Vidal Rodriguez, Cor Lieftink, Lodewyk F.A. Wessels & Roderick L. Beijersbergen. (2016) Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R. Molecular Cancer Therapeutics 15:7, pages 1545-1556.
Crossref
Crossref
Andrew J. Robles, Shengxin Cai, Robert H. Cichewicz & Susan L. Mooberry. (2016) Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer. Breast Cancer Research and Treatment 157:3, pages 475-488.
Crossref
Crossref
Yi-Zhou Jiang, Yi-Rong Liu, Xiao-En Xu, Xi Jin, Xin Hu, Ke-Da Yu & Zhi-Ming Shao. (2016) Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value. Cancer Research 76:8, pages 2105-2114.
Crossref
Crossref
Chen Xu, Hamed Vavadi, Alex Merkulov, Hai Li, Mohsen Erfanzadeh, Atahar Mostafa, Yanping Gong, Hassan Salehi, Susan Tannenbaum & Quing Zhu. (2015) Ultrasound-Guided Diffuse Optical Tomography for Predicting and Monitoring Neoadjuvant Chemotherapy of Breast Cancers. Ultrasonic Imaging 38:1, pages 5-18.
Crossref
Crossref
Hongyan Qian, Jingxiu Xuan, Yuan Liu & Guixiu Shi. (2016) Function of G-Protein-Coupled Estrogen Receptor-1 in Reproductive System Tumors. Journal of Immunology Research 2016, pages 1-6.
Crossref
Crossref
Orsolya Kiss, Anna-Mária Tőkés, Semir Vranic, Zoran Gatalica, László Vass, Nóra Udvarhelyi, A. Marcell Szász & Janina Kulka. (2015) Expression of miRNAs in adenoid cystic carcinomas of the breast and salivary glands. Virchows Archiv 467:5, pages 551-562.
Crossref
Crossref
Quing Zhu, Liqun Wang, Susan Tannenbaum, Andrew Ricci, Patricia DeFusco & Poornima Hegde. (2014) Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteria. Breast Cancer Research 16:5.
Crossref
Crossref
Young Hwa Soung, Kevin Pruitt & Jun Chung. (2014) Epigenetic silencing of ARRDC3 expression in basal-like breast cancer cells. Scientific Reports 4:1.
Crossref
Crossref
Hyae Min Jeon, Do Hee Kim, Woo-Hee Jung & Ja Seung Koo. (2018) Expression of cell metabolism-related genes in different molecular subtypes of triple-negative breast cancer. Tumori Journal 99:4, pages 555-564.
Crossref
Crossref
Sewha Kim, Do Hee Kim, Woo-Hee Jung & Ja Seung Koo. (2013) Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer. Endocrine-Related Cancer 20:3, pages 339-348.
Crossref
Crossref
H.R. Kim, K.H. Jung, S.-A. Im, Y.-H. Im, S.Y. Kang, K.H. Park, S. Lee, S.-B. Kim, K.-H. Lee, J.S. Ahn, S.I. Kim & J.H. Sohn. (2013) Multicentre phase II trial of bevacizumab combined with docetaxel–carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905). Annals of Oncology 24:6, pages 1485-1490.
Crossref
Crossref
Sewha Kim, Do Hee Kim, Woo-Hee Jung & Ja Seung Koo. (2013) Metabolic phenotypes in triple-negative breast cancer. Tumor Biology 34:3, pages 1699-1712.
Crossref
Crossref
Belinda J Cridge, Lesley Larsen & Rhonda J Rosengren. (2013) Curcumin and its derivatives in breast cancer: Current developments and potential for the treatment of drug-resistant cancers. Oncology Discovery 1:1, pages 6.
Crossref
Crossref
Osama HusseinMahmoud MosbahOmar FaroukKamel FaragAiman El-SaedMohammad ArafaAhmed Abdallah. (2013) Hormone Receptors and Age Distribution in Breast Cancer Patients at a University Hospital in Northern Egypt. Breast Cancer: Basic and Clinical Research 7, pages BCBCR.S12214.
Crossref
Crossref
Ghizlane Rais, Soundouss Raissouni, Meryem Aitelhaj, Fadoi Rais, Sara Naciri, Siham Khoyaali, Halima Abahssain, Youssef Bensouda, Basma Khannoussi, Hind Mrabti & Hassan Errihani. (2012) Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology. BMC Women's Health 12:1.
Crossref
Crossref
Sewha Kim, Woo Hee Jung & Ja Seung Koo. (2012) Differences in autophagy-related activity by molecular subtype in triple-negative breast cancer. Tumor Biology 33:5, pages 1681-1694.
Crossref
Crossref
Tadahiro Nozoe, Emiko Mori, Mayuko Kono, Tomohiro Iguchi, Takashi Maeda, Akito Matsukuma & Takahiro Ezaki. (2010) Serum appearance of anti-p53 antibody in triple negative breast cancer. Breast Cancer 19:1, pages 11-15.
Crossref
Crossref
Bernadette C Victor, Arulselvi Anbalagan, Mona M Mohamed, Bonnie F Sloane & Dora Cavallo-Medved. (2011) Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion. Breast Cancer Research 13:6.
Crossref
Crossref
Mark Mackiewicz, Konrad Huppi, Jason J. Pitt, Tiffany H. Dorsey, Stefan Ambs & Natasha J. Caplen. (2011) Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Research and Treatment 130:2, pages 663-679.
Crossref
Crossref
Jin-xue He, Chun-hao Yang & Ze-hong Miao. (2010) Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics. Acta Pharmacologica Sinica 31:9, pages 1172-1180.
Crossref
Crossref
Diponkar Banerjee. (2010) Reinventing Diagnostics for Personalized Therapy in Oncology. Cancers 2:2, pages 1066-1091.
Crossref
Crossref